Nafoxidine

• Description:

  Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.

• Product Name Alternative:

  Nafoxidene

• UNSPSC:

  12352005

• Hazard Statement:

  H302+H312

• Target:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nafoxidine.html

• Purity:

  98.75

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  COC1=CC (CCC (C2=CC=CC=C2) =C3C4=CC=C (OCCN5CCCC5) C=C4) =C3C=C1

• Molecular Formula:

  C29H31NO2

• Molecular Weight:

  425.56

• Precautions:

  H302+H312

• References & Citations:

  [1]Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10 (8) :905-912. |[2]De Lorenzo MS, Farina HG, Alonso DF, Gomez DE. Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 2004;24 (3a) :1737-1743.|[3]Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol. 2004;27 (4) :384-388.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1845-11-0